Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
18
Neutral
6
Bullish
22
Bearish
14
Neutral
0
Bullish
18
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units.
Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability.
The company is strategically pivoting toward a higher-margin Hospital Business, which contributed 49% of revenue in 9M FY26 versus 38% for FY24-25, reflecting an intentional shift in sales mix and dedicated commercial effort to capture fragmented hospital and critical care segments in India.
Vertically integrated manufacturing capacity, EU GMP approvals, and consistent R&D investment (historical annual spend ~₹13 crore and management guidance of ~3% of revenue) underpin Themis Medicare’s product pipeline and aim to support in-house API consumption and external commercial sales as part of growth plans.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,014 Cr
High Risk
0.0
36.7
—
2.8
147.99
65.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Themis Medicare Ltd (THEMISMED) is currently trading at 110.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units. Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability. The company is strategically pivoting toward a higher-margin Hospital Business, which contributed 49% of revenue in 9M FY26 versus 38% for FY24-25, reflecting an intentional shift in sales mix and dedicated commercial effort to capture fragmented hospital and critical care segments in India. Vertically integrated manufacturing capacity, EU GMP approvals, and consistent R&D investment (historical annual spend ~₹13 crore and management guidance of ~3% of revenue) underpin Themis Medicare’s product pipeline and aim to support in-house API consumption and external commercial sales as part of growth plans.
Over the past 52 weeks, Themis Medicare Ltd has traded between a low of ₹65.00 and a high of ₹147.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Themis Medicare Ltd has a market capitalization of approximately 1,014.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Themis Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,014.02 Cr, Themis Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Themis Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Themis Medicare Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
584.55 | 1,166 Cr | 13.26 | 1.54 | 0.31 | 11.60 | 15.18 | 9.87 | ||
331.00 | 1,162 Cr | 27.03 | 15.00 | 0.00 | 51.51 | 27.98 | 10.39 | ||
325.35 | 1,087 Cr | 19.32 | 2.04 | 0.46 | 8.81 | 10.79 | 1.91 | ||
110.10 | 1,014 Cr | 611.67 | 2.77 | 0.45 | 0.42 | 2.70 | 0.19 | ||
1426.00 | 990 Cr | — | 3.07 | 0.07 | -2.54 | -1.83 | -4.45 | ||
25.43 | 972 Cr | 28.57 | 1.86 | 0.39 | 6.52 | 6.49 | -9.84 | ||
197.25 | 960 Cr | 37.32 | 1.81 | 1.51 | 4.85 | 6.56 | 2.83 | ||
| Median: 7 Co. | — | 325.35 | 1,014 Cr | 27.80 | 2.04 | 0.39 | 6.52 | 6.56 | 1.91 |
Regulatory/Compliance Filing
Vividhmargi Trust pledged 2,53,17,620 shares of Themis Medicare (27.49% of total equity; 40.96% of promoter holding) to CTL Trusteeship Limited for Kotak Credit Opportunities Fund Trust on 29-06-2026.
Regulatory/Compliance Filing
Vividhmargi Trust pledged 2,53,17,620 equity shares of Themis Medicare (27.49% of total; 40.96% of promoter holding) on 29-06-2026 in favor of CTL Trusteeship for Kotak Credit Opportunities Fund Trust.
Regulatory/Compliance Filing
Themis Medicare Ltd: Vividhmargi Trust pledged 2,53,17,620 shares (27.49% of total capital; 40.96% of promoter holding) on 29-06-2026 in favour of CTL Trusteeship Ltd (lender: Kotak Credit Opportunities Fund). Revised disclosure filed.
Regulatory/Compliance Filing
Vividhmargi Trust pledged 2,53,17,620 equity shares (27.49% of total; 40.96% of promoter holding) of Themis Medicare on 29-06-2026 to CTL Trusteeship Limited in favour of Kotak Credit Opportunities Fund Trust.
Shareholding Pattern
Themis Medicare: Revised disclosure under Reg.31(1)/(2) reporting release of 1,500,000 pledged equity shares by Vividhmargi Investments Pvt Ltd on 8 July 2026; filings dated 16 & 20 July 2026.
Shareholding Pattern
Themis Medicare: Vividhmargi Investments Pvt Ltd submitted revised SEBI Reg 31 disclosures for release of pledge of 1,500,000 equity shares on 2026-07-08; filings dated 16 & 20 July 2026.
